Gan & Lee’s Insulin Glargine Injection Commercialized in Lebanon-Gan & Lee Pharmaceutical

Company News

Gan & Lee’s Insulin Glargine Injection Commercialized in Lebanon

  • Time: 2020-12-22 11:29:00
  • Click Rate: 2509

Recently, Gan & Lee Pharmaceuticals’ insulin glargine injection has been successfully exported to Lebanon as the drug was approved by Lebanon Ministry of Public Health. Gan & Lee's insulin glargine has been officially commercialized in Lebanon since this first commercial delivery


Since 2005, Gan & Lee Pharmaceuticals has established global business network in more than 20 countries and regions in the world and has built cooperation in Europe, US and other developed countries in 2014. The global business of Gan & Lee is mainly divided into seven areas including North America, Europe, Asia Pacific, Latin American, Commonwealth of Independent States (CIS), Middle Eastern & Northern Africa (MENA) and Sub-Saharan Africa (SSA). 

Looking back to 2020, the company has made remarkable achievement in the global business cooperation. In terms of MENA, Gan & Lee has established partnership with client from Turkey, Lebanon, Niger and other emerging markets. In May, insulin glargine API was first exported to Turkey and, at the same time, the company has successfully obtained the GMP certificate for the new factory issued by Turkey Ministry of Public Health. 

By the end of 2020, insulin glargine injection will be exported to Niger for the first time and commercial shipments of disposable pen parts produced by Gan & Lee’s subsidiary, Gangan Medical Technology Co., Ltd, will be completed. In addition, Gan & Lee has signed cooperation agreements with a number of clients to start the overseas registration of insulin products and medical devices. It is expected that in the near future, Gan & Lee’s business footprint will cover an increasing number of countries in the world.

About Gan & Lee 

Gan & Lee successfully developed the first Chinese domestic biosynthetic human insulin. At present, the company has five recombinant insulin analogs commercialized in China including long-acting glargine (Basalin®), fast-acting lispro (Prandilin®), a mixed protamine zinc lispro injection (25R) (Prandilin®25), fast-acting aspart, and insulin aspart 30 as well as insulin injection pen (reusable).

In the future, Gan & Lee strives to achieve comprehensive coverage in the field of diabetes diagnosis and treatment. Moving forward to advance Gan & Lee’s goal of becoming a world-class pharmaceutical company, we will also take an active part in investigating new chemical entities and biologics to treat cardiovascular disease, metabolic diseases, cancer, and diseases in other therapeutic areas.